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The susceptibility of Pseudomonas aeruginosa to imipenem has been shown to vary according to zinc
concentration in the media. MICs of imipenem for 68 unique clinical isolates of P. aeruginosa were determined
in media supplemented with zinc at concentrations between 0.5 and 6.0 mg/ml. In agar containing up to 3 mg
of zinc/ml, 75 to 82% of the strains were susceptible to imipenem at an MIC of<4 mg/ml. In agar supplemented
to contain 6 mg of zinc/ml, however, only 40% of the strains were susceptible to imipenem. Manufacturers
should ensure that the concentration of zinc in commercial media is below 3 mg/ml to avoid false classification
of isolates as resistant to imipenem.
Imipenem (N-formimidoyl thienamycin), a member of the
carbapenem class of antibiotics, has activity against a broad
spectrum of organisms that includes Pseudomonas aeruginosa.
Traditionally, serious infections due to this organism require
the administration of two effective antimicrobial agents to
achieve cure and to help prevent the development of resistance
during treatment (4). Accurate detection of resistance of P.
aeruginosa to imipenem by the clinical microbiology laboratory
is critical for proper use of this antibiotic (9).
Unfortunately, in vitro testing of imipenem has been prob-
lematic, partly because of the instability of this compound in
the commercially prepared dry-format, predried broth, and
frozen microdilution panels that are used by many laboratories
for susceptibility testing (1, 3, 5, 8). Baron and Hindler showed
that the bioactivity of imipenem in these panels is dependent
upon the type of medium used and on the time and tempera-
ture of incubation (1). Other investigators found additional
factors that affect the reliability of imipenem bioactivity tests:
variations in lots of Mueller-Hinton broth (MHB), multiple
passaging of the control strain of P. aeruginosa, and moisture in
stored dry-format panels (5, 8, 9).
A study by Cooper and colleagues reported that zinc con-
centration in commercial media influenced the susceptibility of
P. aeruginosa and other gram-negative bacilli to imipenem (2).
They found that a Mueller-Hinton agar (MHA) with a higher
zinc concentration (2.62 mg/ml) was associated with a higher
MIC of imipenem for P. aeruginosa, reaching concentrations
that are greater than or equal to the susceptibility breakpoint
of 16 mg/ml established by the National Committee for Clinical
Laboratory Standards (NCCLS), resulting in misclassification
of susceptible strains as resistant (2). However, it appears that
the changes in MICs were within a onefold dilution for many
strains and within the inherent error of the assay. In addition,
Cooper et al. tested media with differences other than zinc
concentration alone obtained from different manufacturers. In
this study, we attempted to document the findings of Cooper
et al. and to determine whether higher zinc concentrations
in MHA independently increase the MIC of imipenem for
P. aeruginosa.
(This data was presented in part at the 96th General Meet-
ing of the American Society for Microbiology held in New
Orleans, La., 19 to 23 May 1996.)
Methods and materials. Sixty-eight unique clinical strains of
P. aeruginosa were collected from The Medical Center of Cen-
tral Massachusetts, Worcester, Mass. Thirty-four strains were
collected from 3 October 1986 to 25 June 1993 and were taken
from our frozen collection, and 34 strains were recent clinical
isolates collected from 19 November 1994 to 8 February 1995.
Control strains, P. aeruginosaATCC 27853 and Escherichia coli
ATCC 25922, were tested throughout the study. Bacterial iso-
lates were stored at 2708C in semisolid brain heart infusion
agar (Difco Laboratories, Detroit, Mich.). Isolates were grown
overnight at 358C on Trypticase soy agar with 5% sheep blood
(BBL Microbiology Systems, Cockeysville, Md.).
Plates for agar dilution testing were prepared by using imi-
penem reference powder (Merck and Co., Inc., West Point,
Pa.; lot 7058A) and MHB plus 17 g of Bacto-Agar (Difco
Laboratories, Detroit, Mich.) per liter. Concentrations of imi-
penem tested were 0.06 to 125 mg/ml. The media used in the
study were BBL MHB (BBL Microbiology Systems) and Difco
MHB (Difco Laboratories). The Difco brand of MHB con-
tained the lowest concentration of zinc and was supplemented
with zinc acetate dihydrate (Sigma Chemical Company, St.
Louis, Mo.) to achieve final concentrations of 6.0, 3.0, 2.0, 1.0,
and 0.5 mg of zinc/ml in the agar. An aliquot of each concen-
tration was sent to Merck and Co., where the actual zinc
content in the broth was determined by an inductively coupled
plasma-atomic emission spectroscopy method. Solutions con-
taining imipenem were used immediately to avoid deteriora-
tion before testing.
Agar dilution testing was performed in accordance with
NCCLS guidelines (7). Colonies of each bacterial isolate were
suspended in MHB to match a 0.5 McFarland standard. The
suspensions were then diluted 1:10 and inoculated onto anti-
biotic-containing agar plates by using a Steers replicator to
deliver approximately 104 CFU per spot. The plates were in-
cubated at 358C for 16 to 20 h. MICs were determined as the
lowest concentration of antimicrobial agent that completely
inhibited growth, disregarding a single colony or a faint haze
caused by inoculum (7). Agar dilution testing of imipenem
against 68 clinical isolates of P. aeruginosa was conducted si-* Corresponding author.
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multaneously on BBL MHA, Difco MHA, and Difco MHA
supplemented with 6.0, 3.0, 2.0, 1.0, and 0.5 mg of zinc/ml.
Results. The actual zinc concentration was measured by
inductively coupled plasma-atomic emission spectroscopy. The
zinc content of Difco MHA was 0.2 mg/ml. In zinc-supple-
mented media, the measured zinc content was 618% of the
target concentration for all solutions tested.
Table 1 shows the cumulative percentages of 68 strains of P.
aeruginosa that were susceptible to increasing concentrations
of imipenem when tested with BBL MHA, Difco MHA un-
supplemented with zinc, and Difco MHA supplemented with
0.5, 1.0, 2, 3, and 6 mg of zinc/ml. The percentage of isolates
susceptible to imipenem at various concentrations was similar
for Difco unsupplemented MHA (zinc concentration 5 0.2
mg/ml) and for MHA supplemented with 0.5 mg of zinc/ml.
There was no notable difference in susceptibility to imipenem
when agar dilution testing was performed on media supple-
mented with zinc at concentrations of 0.5 versus 1.0 and 2
versus 3 mg/ml.
Table 2 illustrates the influence of various zinc concentra-
tions in MHA on susceptibility of the 68 P. aeruginosa isolates
to imipenem. The number of isolates that were resistant (9 to
15%) remained generally constant throughout the study. The
most notable difference in susceptibility occurred when MHA
was supplemented with 6 mg of zinc/ml, at which concentration
51% of the strains were classified as intermediate; in contrast,
3 to 12% of the strains were intermediate when tested in all
other types of media with lower zinc concentrations. For clas-
sification as susceptible, 75 to 82% of the strains were suscep-
tible to imipenem in all media except MHA supplemented with
6 mg of zinc/ml, in which only 40% of strains were susceptible.
Figure 1 illustrates the degree of change in MIC of imipenem
when P. aeruginosa isolates were tested by using MHA with
zinc at concentrations of 3 and 6 mg/ml.
Discussion. Cooper and colleagues (2) reported that the zinc
concentration in MHA can increase the MIC of imipenem for
P. aeruginosa, often to concentrations that are greater than or
equal to the susceptibility breakpoint of 16 mg/ml established
by NCCLS (7). They noted that the effects of high zinc con-
centration varied in media from different manufacturers. Coo-
per et al. concluded that this finding was clinically significant
despite the fact that the difference seen was a onefold dilution
when the broth dilution method was used. Their conclusion
was valid for strains for which the MIC was at the breakpoint
of interpretive susceptibility criteria (between 4 and 16 mg/ml),
where a shift of one twofold dilution can change the interpre-
tation from “susceptible” to “intermediate” or from “interme-
diate” to “resistant.” For 95% of the strains they tested, the
MIC was less than or equal to 8 mg/ml when a low-zinc medium
(Difco) was used, and for 93%, the MIC was less than or equal
to 16 mg/ml when a medium with a higher zinc concentration
(2.61 mg/ml; BBL) was used. Given the limits of reliability of
agar dilution testing, we were concerned that the effect of zinc
was unclear and that a concentration of 3 mg/ml did not pro-
duce a clinically significant difference in the MICs for most
strains.
An increase in the amount of zinc in MHA correlates in vitro
with an increase in the MIC of imipenem, but it is not known
if zinc levels in humans influence imipenem in vivo antibacte-
rial activity. The normal concentration of zinc in serum is 12
mmol/l or 0.8 mg/ml (6). The danger of misreporting strains as
intermediate or resistant is that clinicians have limited antibi-
otic choices when treating patients with Pseudomonas infec-
tions and imipenem represents a necessary therapeutic option,
often as a part of a multidrug regimen. However, at zinc con-
centrations of 3 mg/ml and below, differences in MICs were not
clinically relevant, except for strains for which MICs are near
the breakpoint for classification as intermediate or resistant.
FIG. 1. Changes in MIC of imipenem for P. aeruginosa isolates in MHA with
various zinc concentrations.
TABLE 1. Susceptibility of 68 strains of P. aeruginosa to increasing
concentrations of imipenem when tested in media containing
measured amounts of zinc
Imipenem
concn
(mg/ml)
% of strains susceptiblea with zinc concn (mg/ml) of:
0.2 0.5 1 2 3 6
0.25 2 2 0 0 0 0
0.5 2 2 0 2 0 0
1.0 47 44 43 25 7 0
2 75 78 71 57 51 3
4 82 81 82 77 75 40
8 85 87 85 87 87 91
16 96 96 96 96 97 100
32 100 100 100 100 100 100
a Cumulative percentage of 68 strains.
TABLE 2. Susceptibility of Pseudomonas isolates at various
zinc concentrations
Concn (mg/ml) of zinc in
Difco medium
No. of strains (%)a
S I R
None (unsupplemented) 56 (82) 2 (3) 10 (15)
0.5 55 (81) 4 (6) 9 (13)
1.0 56 (82) 2 (3) 10 (15)
2.0 52 (76) 7 (10) 9 (13)
3.0 51 (75) 8 (12) 9 (13)
6.0 27 (40) 35 (51) 6 (9)
a S, susceptible; I, intermediate; R, resistant.
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Similarly, while at least 75% of all strains were inhibited by 4
mg of imipenem/ml in media supplemented with 0.5, 1, 2, and
3 mg of zinc/ml, fewer than half (40%) of the 68 strains were
inhibited by 4 mg of imipenem/ml in MHA supplemented with
6 mg of zinc/ml. This suggests that by controlling the amount of
zinc in media, manufacturers can prevent erroneous reporting
by the microbiology laboratory of resistance to imipenem.
We thank Xueguang Fang of Merck and Company, Inc., for mea-
surement of zinc concentrations in the media.
Merck and Company, Inc., provided financial support for the
project.
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